Make an appointment with a cancer specialist today.
Call us at 800-KARMANOS (800-527-6266)
Home / Physicians & Research / Professional Education / Neuroendocrine Tumor Regional Conference

Neuroendocrine Tumor Regional Conference

Multidisciplinary Management of NET Cancers

This event is hosted in partnership with the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine and the North American NeuroEndocrine Tumor Society.

Date & Location

Saturday, May 17, 2014
7:30 am to 3:45 pm

Marriott Hotel Troy
200 West Big Beaver Road
Troy, Michigan 48084

Conference rates will be offered from May14 through May 20, 2014 based on availability. For reservations call 1-866-539-8117 and mention your attendance at the NANETS conference to receive the group rate. For online reservations, go to www.nanets.net, conference details, and then to the link: Detroit Marriott Troy - Reservations & Accommodations.

Registration & Cost

  • Physicians: $50
  • Other Medical Professionals: $25
  • Residents, Fellows and Students are Complimentary
  • Register Online Now

Registration forms and payment instructions are on the website, www.nanets.net.
Attendees are responsible for all airfare, lodging, and transportation costs. The program fee includes: Catered break, breakfast and lunch and all instructional materials. To help meet administrative costs, a service charge of $25 will be assessed on all refund requests received by May 07, 2014. No refunds can be issued after that date. Should conditions warrant, the sponsors reserve the right to cancel this program with a full tuition refund.

Please register early as enrollment will be limited. If you require special assistance, please contact Kari at 360-314-4112.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Wayne State University School of Medicine and
the North American Neuroendocrine Tumor Society. The Wayne State School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.The Wayne State University School of Medicine designates this educational activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives

Upon completion of this program the participant will gain improved understanding of:

  • Interpret current advances in the histopathology of both primary & metastatic NETs and how classification determines diagnostic approach, management and prognosis
  • Utilize the proper assays & diagnostic techniques for identifying and monitoring NET diseases;
  • Describe the various surgical interventions for different NET sites and define the importance of incorporating an evaluation by an experienced NET surgeon into the patient’s ongoing treatment plan;
  • Evaluate the safety and efficacy of image guided diagnostics or treatment and determine when to integrate the procedure(s) into a patient's treatment plan;
  • Specify the risks and benefits of each liver directed therapy based on patient-specific information;
  • Identify the numerous syndromes associated with neuroendocrine tumors and define the symptoms related to each condition;
  • Compare the clinical effectiveness of the different targeted therapies and radiotherapeutic approaches to assess which intervention would be most appropriate for patients with different neuroendocrine tumors;
  • Illustrate the value of creating a multidisciplinary team and communication system to improve the quality of care for the NET patients.

Agenda

7:30 – 8:15am
Registration and Continental Breakfast 
8:15 – 8:20am
Introduction
Philip A. Philip, MD, PhD, FRCP
8:20 – 9:40am
Presentation and Diagnosis
  • Overview of Carcinoid Tumors and Other NETs – Laura H. Tang
    • General Background & Epidemiology

  • Pathology- Laura H. Tang, MD
    • General Features
    • Organ Specific Issues
    • Grading, Staging and Classification
    • Minimum Pathology Data Set

  • Diagnosis of NETs
    • Endoscopy & Colonoscopy – Fadi Antaki, MD
    • Biomarkers: Interpreting Laboratory Results to Clinical Use - Fadi Antaki, MD
    • Obstacles In Diagnosis For the Clinician - Fadi Antaki, MD
    • Radiological Imaging – Selecting the Right Procedure & Contrast Agents - Anthony F. Shields, MD, PhD
    • Nuclear Imaging - Which Techniques are Most Efficient for Localizing Tumors? Anthony F. Shields, MD, PhD
    • Q & A
9:40 – 11:00am
Surgical Options: Making the Right Choice
  • Surgical Intervention of NETs
    • Potential for Crisis & Octreotide Protocol – Rodney F. Pommier, MD
    • Surgery for Stomach, Small Bowel, Appendiceal and Rectal NETs - Rodney F. Pommier, MD
    • Removal of Primary & Mesenteric Nodal Mass - Rodney F. Pommier, MD
    • Surgery for Pancreatic Endocrine Tumors – Steve H. Kim, MD, FACS
    • Resection of Liver Mets & Laparoscopy – Marwan Kazimi, MD
    • Q & A
11:00 – 11:15am  Break
11:15 – 11:45am The Role of Interventional Radiology in the Diagnosis & Management of NETs
  • Diagnosis of NETs – Jeffrey J. Critchfield, MD
    • Image guided biopsy
    • CT/Ultrasound/MRI guided treatment
  • Management of Hepatic Metastases – Jeffrey J. Critchfield, MD
    • Embolotherapy & Ablation
    • Q & A
11:45am – 1:00pm
Management of Hormonal Syndromes from NETs
  • Functioning & Non Functioning Pancreatic NETs – David C. Metz, MD
  • Carcinoid Syndrome - Rodney F. Pommier, MD
    • Symptomatic Control (octreotide, lanreotide, pasireotide,telotristat etiprate)
    • Disease Stabilization and Improved Survival (PROMID & CLARINET study)
    • Managing Persistent/Recurrent Diarrhea
    • Carcinoid Heart Disease
    • Q & A
1:00 – 2:00pm
Lunch
2:00 – 3:00pm
Medical Management of NETs
  • Systemic Therapies
    • Overview Cytotoxic Therapies – Philip A. Philip, MD, PhD, FRCP
    • Clinical Development of VEGF Pathway & mTOR Inhibitors in NETs - Philip A. Philip, MD, PhD, FRCP
    • Peptide Receptor Radionuclide Therapy –Current Status in US – David C. Metz, MD
    • Other Current Clinical Trials – David C. Metz, MD
    • Q & A
3:00 – 3:45pm
Developing a Multidisciplinary Team & Case Presentations - Philip A. Philip, MD, PhD, FRCP & Panel
  • Q & A

Planning Committee

Philip A. Philip, M.D., PhD, FRCP
Barbara Ann Karmanos Cancer Institute
Wayne State University School Of Medicine 
Kari Brendtro
North American NeuroEndocrine Tumor Society

More Information

For further information, please contact Kari at 360-314-4112.

© 2014 Karmanos Cancer Institute Pencil
The Barbara Ann Karmanos Cancer Center is accredited by The Joint Commission.
If members of the public have any quality-of-care or safety concerns, they may notify The Joint Commission at 630-792-5800.